Sleeping Bruxism Treatment Market Research Report—Global Forecast till 2030

Sleeping Bruxism Treatment Market Research Report: Information by Type (Primary Bruxism, Secondary Bruxism), by Treatment (Dental Approaches, Medication), by Cause (Obstructive Sleep Apnea, Gastroesophageal Reflux Disease (GERD), Malocclusion, Sleep Paralysis), by Patient Type (Pediatric, Adult), by End User (Hospitals & Clinics, Dental Clinics) and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa) - Forecast till 2030

ID: MRFR/HC/3979-CR | December 2021 | Region: Global | 130 Pages         

Sleeping Bruxism Treatment Market Speak to Analyst Request a Free Sample

Sleeping Bruxism Treatment Market

Sleeping bruxism treatment market is expected to register a CAGR of 5.95 % with USD 934.90 Million by 2030

By Type Primary Bruxism Secondary Bruxism
By Diagnosis Clinical Examination Polysomnography
By Treatment Dental Approaches Treatment Drugs
By Cause Obstructive Sleep Apnea GERD Malocclusion Sleep Paralysis
By Patient type Pediatric Adult
Key Players
Companies Profiled   Ivoclar Vivadent AG (Liechtenstein)   Ipsen S.A. (France)   Merz Pharma GmbH & Co. KGaA (Germany)   Carestream Dental (US)   Akervall Technologies Inc (US)   Planmeca Oy (Finland)   Randmark Dental Products    LLC (US)   S4S (UK) Limited (UK)   Patterson Dental Supply Inc (US)   Henry Schein Inc (US)
Market Driving Forces   Increasing prevalence of sleep bruxism   Growing child population   Rising prevalence of obstructive sleep apnea   Lifestyle changes
Request a Free Sample

Sleeping Bruxism Treatment Market Overview:

Sleeping Bruxism Treatment Market size is projected to be worth USD 934.90 million by 2030, registering a CAGR of 5.95% during the forecast period (2021 - 2030)

Sleeping bruxism is a chronic sleep related movement disorder which is characterized by clenching of the jaw, teeth and cheek during sleep. The common symptom of this disease is tooth wear on the upper front teeth. It can also cause soreness in the neck muscle and headaches. The treatment of sleep bruxism includes holding dental guard to keep patient mouth closed during sleep which reduces risk of anxiety or stress.

The growth of the global sleeping bruxism treatment market is attributed to the increasing prevalence of sleep bruxism, growing child population, rising prevalence of obstructive sleep apnea and lifestyle changes. However, limited availability of treatment options is hampering the market growth. Also, untapped markets in Asia-Pacific provide viable opportunities for market growth in the future.

COVID-19 Analysis

The stress caused due to variable factors during the pandemic increased the demand for sleeping bruxism treatment. The health experts found that stress, anxiety, insomnia are the major factors that augmented the number of sleeping bruxism cases. Sleeping bruxism may lead to tooth fractures in serious cases. Moreover, the dental appointments and consulting services rose in the mid of the pandemic as a large number of the patients were experiencing pain and teeth grinding issues. These factors accelerated the demand for sleeping bruxism treatment across the world. However, improvement in networking and communication infrastructure supported the telehealth platforms, thereby helping patients and doctors in face-to-face consulting. The hospitals, dental clinics, and ambulatory centers are functional for emergency cases such as immediate discomfort in the jaw joints, tooth fractures, and increased agony in the facial muscular worldwide. Hence, there is a rise in the immediate sleeping bruxism treatment, including Botox injections, anti-anxiety/anti-depressants drugs, bite guards, nonsteroidal anti-inflammatory drugs (NSAIDs), and heat packs.

Market Dynamics

  • Increasing prevalence of sleeping bruxism

    • Since the past few years, the prevalence of sleeping bruxism has increased. A research article was published in 2017 in the Journal of Oral rehabilitation assessing the Dutch adolescent population. It mentioned the prevalence of 4.2% for awake bruxism and sleep bruxism in the range of 7.6% to 13.2%. In the presence of such trends, the reported cases of headaches and tooth wear due to sleep bruxism are estimated to increase, thereby mounting a negative impact on the patients' lives. Few effective ways to avoid such complications associated with the disease include administering medications, antidepressants, and muscle relaxants and wearing a mouthguard. Thus, the increasing prevalence of sleeping bruxism is subsequently increasing the demand for the available therapeutic options. Conclusively, it is expected to provide favorable backgrounds for the market to grow during the forecast period.

  • Growing child population

  • Rising prevalence of obstructive sleep apnea

  • Lifestyle changes

Market Restraints

  • Limited Availability of Treatment Options

    • Medications are not very effective for treating sleeping bruxism. In such circumstances, it becomes important to manage the consequences of the disorder by the available preventative measures, which involve the application of mandibular advancement devices, occlusal splints, stress management, drugs, occlusal splints, and others. A variety of medications, such as anti-anxiety drugs and muscle relaxants, are significantly employed to treat sleeping bruxism. However, it is reported that such medication options come with the capping of side effects such as constipation, nausea, and muscle weakness, amongst others. Following the same course, it is evident that bruxism mouthguards ground down with time during bruxism episodes. Thus, it is estimated that the available treatment options are not effective and incorporates side effects, making the patients reluctant to opt for the available treatment options.

Market Opportunities

  • Untapped Markets in Asia-Pacific

    • The markets in Asia-Pacific have a relatively low penetration for sleep bruxism products. In recent years, the healthcare sector within the region has witnessed huge investments, thereby expanding the dental industries in developing economies such as India, China, and Australia. The overall Indian healthcare industry has witnessed a rapid change backed by the rising demand for superior quality healthcare products in the country. According to the World Dental Show in 2017, the Indian dental industry was estimated to reach USD 242.81 million at a positive CAGR of 16.0% by the end of 2018. Such growth in the dental industry is estimated to be seen as an opportunity by market players to launch new and technologically advanced products within the regional boundaries of Asia-Pacific region. Moreover, many cases of sleeping bruxism occur in comorbid conditions with Obstructive Sleep Apnea (OSA). In 2018, according to the SNORE AUSTRALIA, ~9.0% of women and 25.0% of men in Australia had clinically significant obstructive sleep apnea. 

Value Chain Analysis

  • The global sleeping bruxism treatment market is showing positive growth, owing to the increasing workplace stress, changing lifestyle, and rising prevalence of obstructive sleep disorders such as sleep apnea, insomnia, and excessive sleepiness. The value chain analysis for the market comprises four major components, which start with the research & development and product designing, manufacturing, distribution & sales and post-sales review.

Segment OverviewBy Type

  • Primary Bruxism

    • Primary bruxism occurs in the absence of any medical condition. It is associated with social psychological factors, dysfunction of the basal ganglia, tooth interference, and genetic influences. In primary bruxism, chewing muscle activity and the autonomic nervous system is triggered by sleep arousals that eventually lead to teeth grinding.

  • Secondary Bruxism

    • Secondary bruxism occurs in the presence of some neurological disorder, medical or psychiatric condition, or due to a side effect of drugs. Sleeping bruxism is highly found in people who consume psychoactive substances. According to the CDC, from 2015 to 2018, around 13.2% of adults used antidepressants; higher use was seen among women, around 17.7% than men, which is around 8.4%. According to the National Institute of Neurological Disorders and Stroke, there are more than 600 neurologic disorders, with approximately 50 million Americans affected each year.

By Cause

  • Obstructive Sleep Apnea

    • According to National Sleep Foundation, one in four people with Obstructive Sleep Apnea (OSA) clench their teeth in sleep. A research article published in the Journal of Clinical Medicine in 2019 carried out a study to understand the relationship between OSA and sleep disorders such as sleeping bruxism. The study concluded that there was a relationship between OSA and Sleep Bruxism (SB) that also depends on the degree of severity of OSA.

  • Gastroesophageal Reflux Disease (GERD)

    • Gastroesophageal Reflux Disease (GERD) is a digestive disorder that affects the population of every age, from infants to older adults. Sleep bruxism is commonly observed in GERD patients; sleep apnea causes gastric acid to leak into the esophagus, which further triggers micro-arousals, eventually leading to sleep bruxism. A data published in 2018 in PubMed describes the association between GERD and patients with sleep bruxism (SB). Bruxism is strongly associated with GERD patients with frequent bruxism symptoms. Such association between GERD and SB is fueling the market growth of this segment.

  • Malocclusion

    • Malocclusion is a misalignment of teeth caused due to childhood habits such as thumb sucking and imposes functional and aesthetic disturbances. According to an article published in 2020, the etiology of bruxism is multifactorial; that is, it is the combination of local, systemic, psychological, occupational, and hereditary factors. The article studied the prevalence of sleep bruxism and reported that the prevalence of sleep bruxism was 22% in the study population and was associated with malocclusions. Such studies focused on understanding the association between sleep bruxism and malocclusion is driving this segment's growth.

  • Sleep Paralysis

    • Sleep Paralysis (SP) is linked with sleeping bruxism, and patients tend to grind their teeth if they have a sleeping disorder such as sleep talking, sleep paralysis, and sleep hallucinations. According to CDC, the sleep paralysis can affect around 7.6% of the general population during their lifetime, and it is a common condition worldwide. Hence, the increasing prevalence of sleep paralysis and its association with sleep bruxism is boosting the growth of this segment.

By Treatment

  • Dental Approaches

    • Dental approaches are the first-line treatment given to sleeping bruxism patient and includes splints and mouth guards. Mouth guards help to reduce the pressure on the jaw and teeth whereas occlusal splints are used to prevent primary sleep bruxism. Splints cover the whole maxillary or mandibular dental arch that reduces the masticatory events per hour of sleep. The dental approach also includes dental correction.

  • Medication

    • On the basis of its type of medication, the global sleep bruxism market is segmented into muscle relaxants, Botox injections, and anti-anxiety drugs. Muscle relaxant treatment includes injecting the muscle relaxant into the masseter muscle, which weakens the muscle and eventually reduces the grinding of teeth. Treatment with Botulinum Toxin Type A is called Botox treatment and relieves the patient from jaw soreness, headaches, and other problems of bruxism. A small amount of Botox is injected into the masseter muscle which weakens the muscle and prevents the involuntary grinding of teeth.

By Patient Type

  • Pediatric

    • Sleep bruxism occurs in children when they are deep in sleep and are under stress. Additionally, anger and nervousness lead to bruxism in kids. According to Kids Health, 3 out of every ten children suffer from sleep bruxism. Moreover, as stated by the Journal of Family Medicine and Primary Care in 2020, sleep bruxism is a frequent parasomnia encountered by children. The increasing pediatric population suffering from sleep bruxism is boosting the market growth of this segment.

  • Adult

    • Awake bruxism and sleep bruxism are common conditions found among adult populations. Also, women reported both awake bruxism and sleep bruxism more often than men. Sleep bruxism affects males and females in equal proportions. Sleep bruxism in adults is mainly caused due to anxiety, alcohol consumption, cigarette smoking, stress, caffeine, obstructive sleep apnea, and fatigue. The increasing adult population suffering from bruxism is fueling the market growth of this segment.

By End User

  • Hospitals & Clinics

    • With developing medical technology, hospitals and clinics are providing treatments such as consultation, psychoanalysis, and progressive relaxation. Hospitals and clinics carry out a diagnosis of sleep bruxism as they carry out a clinical examination, electromyographic recordings, and imaging. Hospitals and clinics dominate the global market due to increasing demands for the treatment of sleep bruxism.

  • Dental Clinics

    • Dental clinics offer mouth guards, splints, orthodontic treatment, and dental corrections. The increasing use of teeth restoration in dental clinics accounts for a major market share in the sleep bruxism treatment market. Moreover, the increasing prevalence of dental problems such as malocclusion and teeth grinding during sleep have also increased the number of dental clinics involved in treating sleeping bruxism, which contributes to market growth in this segment.

Regional AnalysisFigure: GLOBAL SLEEPING BRUXISM TREATMENT MARKET SHARE (%), BY Region, 2020Sleeping Bruxism Treatment Market By Region 2020Americas

  • The Americas accounted for the largest market share in 2020 in the global sleeping bruxism treatment market, owing to the rising prevalence of sleeping bruxism, rising stress and anxiety among the population

  • According to the Anxiety & Depression Association of America, anxiety disorders affect about 40 million adults in the US, or 18.1% of the population every year. Moreover, according to the National Institutes of Health, more than 40 million Americans suffer from chronic, long-term sleep disorders, and an additional 20 million report sleeping problems occasionally. Furthermore, the American Sleep Association estimates that sleeping bruxism affects 10% of the adult population and 15% of the children population. Hence, the Americas market is expected to reach USD 318.70 million by 2027 at a CAGR of 6.47% from 2021–2027.


  • Asia-Pacific is expected to grow rapidly in the sleeping bruxism treatment market owing to the growing adoption of advanced healthcare technology and rising child population

  • According to UNICEF, in 2016, South Asia has 627 million children, i.e., 36% of the total population. Moreover, raising awareness of sleep bruxism and rapidly growing dental industry in countries such as China, India, Japan, and South Korea is likely to fuel the market growth. Furthermore, there has been a growing prevalence of mental illness, including stress, anxiety, and depression, and sleep-related disorders such as sleep apnea in the region. These factors contribute to market growth in Asia-Pacific region.

Competitive Landscape

  • The global sleeping bruxism treatment market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products to survive and succeed in an intensely competitive market environment.

List of companies with HQ

  • Ivoclar Vivadent AG (Liechtenstein)

  • Ipsen S.A. (France)

  • Merz Pharma GmbH & Co. KGaA (Germany)

  • Carestream Dental (US)

  • Akervall Technologies Inc (US)

  • Planmeca Oy (Finland)

  • Randmark Dental Products, LLC (US)

  • S4S (UK) Limited (UK)

  • Patterson Dental Supply, Inc (US)

  • Henry Schein, Inc (US)

  • Pfizer, Inc (US)

Recent Developments

  • In January 2021, Henry Schein, Inc. acquired majority ownership position in Prism Medical Products, LLC (PRISM), a nationwide provider of specialty home medical supplies. With this transaction, Henry Schein Medical, the US medical division of Henry Schein, Inc., enters an established and growing multibillion-dollar market for home medical equipment and supplies.

  • In June 2020, Carestream Dental entered into a partnership with Unified Smiles, a management consulting firm based in the US. Under the partnership, Carestream Dental will provide support, guidance, and education to independent practices.

Report Overview

  • The study covers the existing short-term and long-term market effects. It helps decision-makers to draught short-term and long-term business plans by region. The report covers major regions in Americas, Europe, Asia-Pacific, and the Middle East and Africa. The report analyzes market drivers, restraints, opportunities, challenges, Porter's five forces, value chain, and impact of COVID-19 on the market.

Study Objectives

  • To provide a comprehensive analysis of the global sleeping bruxism treatment market and its sub-segments, thereby providing a detailed structure of the industry

  • To provide detailed insights into factors driving and restraining the growth of the global sleeping bruxism treatment market

  • To estimate the market size of the sleeping bruxism treatment market where 2018 to 2019 would be the historical period, 2020 shall be the base year, and 2021 to 2027 will be forecast period for the study

  • To provide strategic profiling of key companies (manufacturers and distributors) present across the countries, and comprehensively analyze their competitiveness/competitive landscape in this market

  • To provide a value chain analysis for the sleeping bruxism treatment market.

Market Segmentation:Global Sleeping Bruxism Treatment Market, By Type

  • Primary Bruxism

  • Secondary Bruxism

Global Sleeping Bruxism Treatment Market, By Cause

  • Obstructive Sleep Apnea

  • Gastroesophageal reflux disease (GERD)

  • Malocclusion

  • Sleep Paralysis

Global Sleeping Bruxism Treatment Market, By Treatment

  • Dental Approaches

    • Mouth Guard

    • NTI-TSS Device

  • Medication

  • Muscle Relaxants

  • Botox Injections

  • Anti-anxiety Drugs

Global Sleeping Bruxism Treatment Market, By Patient Type

  • Pediatric

  • Adult

    • Male

    • Female

Global Sleeping Bruxism Treatment Market, By End User

  • Hospitals & Clinics

  • Dental Clinics

Global Sleeping Bruxism Treatment Market, By Region

  • Americas

    • US

    • Canada

  • South America

  • Europe

    • Western Europe

      • Germany

      • France

      • UK

      • Scandinavia

      • Benelux Union

      • Italy

      • Spain

      • Switzerland

      • Rest of Western Europe

    • Eastern Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • Middle East and Africa

    • Middle East

    • Africa

Intended Audience

  • Manufacturers and distributors

  • Healthcare institutions (hospitals, laboratories, medical schools, and outpatient clinics)

  • Research institutes

  • Contract Manufacturing Organizations (CMOs)

  • Government associations

  • Market research and consulting firms

  • Venture capitalists and investors

Report Scope:

Report Attribute/Metric Details
  Market Size   2027: USD 934.90 Million
  CAGR   5.95%
  Base Year   2020
  Forecast Period   2020-2030
  Historical Data   2018 & 2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, Test Type, End User, and Region
  Geographies Covered   Americas, Europe, Asia-Pacific, and Middle East and Africa
  Key Vendors   Ivoclar Vivadent AG (Liechtenstein), Ipsen S.A. (France), Merz Pharma GmbH & Co. KGaA (Germany), Carestream Dental (US), Akervall Technologies Inc (US), Planmeca Oy (Finland), Randmark Dental Products, LLC (US), S4S (UK) Limited (UK), Patterson Dental Supply, Inc (US), Henry Schein, Inc (US), Pfizer, Inc (US), and others
  Key Market Opportunities   â€¢ Untapped Markets in Asia-Pacific
  Key Market Drivers   â€¢ Increasing prevalence of sleep bruxism • Growing child population • Rising prevalence of obstructive sleep apnea • Lifestyle changes

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Sleeping bruxism treatment market projected to grow at approximately 5.95% CAGR during the assessment period (2020-2030).

The valuation of the sleeping bruxism treatment market is estimated to increase to USD 934.90 MN by the end of 2030.

Increasing prevalence of the disorder and growing funding & healthcare insurance coverage, are major tailwinds pushing the growth of the sleeping bruxism treatment market.

North America holds the largest share in the sleeping bruxism treatment market, followed by Europe and the Asia Pacific, respectively.

Ipsen Biopharmaceuticals, Inc., Pfizer Inc., Ivoclar Vivadent AG, Henry Schein, Inc., Merz Pharma GmbH & Co. KGaA, Carestream Dental, Patterson Dental Supply, Inc., S4S Dental Laboratory, Akervall Technologies Inc., PLANMECA OY, and Randmark Dental Products, LLC, are some of the top players operating in the global sleeping bruxism treatment market.